A Phase 1 interventional study of Selpercatinib in Healthy and Hepatic Impairment, sponsored by Eli Lilly and Company. Completed at 7 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-13.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to assess how selpercatinib gets into the blood stream and how long it takes the body to remove it when administered to participants with impaired hepatic function compared to healthy participants. Information about safety and tolerability will be collected. The study will last up to about 7 weeks, inclusive of screening period.
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males who are capable of fathering a child must agree to use one of the following methods of contraception from the time of the dose administration through 6 months after dose administration:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 mg selpercatinib administered orally to healthy participants after at least a 2-hour fast on Day 1.
Drug: Selpercatinib
160 mg selpercatinib administered orally to participants with mild hepatic impairment per Child-Pugh \[CP\] classification (CP Class A, score of 5 or 6) after at least a 2-hour fast on Day 1.
Drug: Selpercatinib
160 mg selpercatinib administered orally to participants with moderate hepatic impairment per CP classification (CP Class B, score of 7 to 9) after at least a 2-hour fast on Day 1.
Drug: Selpercatinib
160 mg Selpercatinib administered orally to participants with severe hepatic impairment per CP classification (CP Class C, score of 10 to 15) after at least a 2-hour fast on Day 1.
Drug: Selpercatinib
Administered orally.
Also known as: LY3527723, LOXO-292
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib
PK: Cmax of selpercatinib was reported.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Time to Reach Cmax (Tmax) of Selpercatinib
PK: Tmax of Selpercatinib was reported.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Area Under the Concentration-time Curve (AUC), From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
PK: AUC0-t was calculated using the linear trapezoidal rule for increasing and decreasing concentrations.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: AUC Extrapolated to Infinity (AUC0-∞) of Selpercatinib
PK: Area under the plasma concentration time curve extrapolated to infinity, calculated as AUC(0-t) + Ct/λZ, where Ct is the last measurable concentration and λZ is the apparent terminal elimination rate constant.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Percentage Extrapolation for AUC (%AUCextrap) of Selpercatinib
PK: %AUCextrap of Selpercatinib was reported.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Apparent Terminal Elimination Rate Constant (λz) of Selpercatinib
PK: Apparent terminal elimination rate constant, where λZ is the magnitude of the slope of the linear regression of the log concentration versus-time profile during the terminal phase.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Apparent Terminal Elimination Half-life (t1/2) of Selpercatinib
PK: Apparent terminal elimination half-life (whenever possible), where t1/2 = natural log (ln)(2)/λZ.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Apparent Systemic Clearance (CL/F) of Selpercatinib
CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC (0-inf), expressed in liter/hour (L/hr).
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Apparent Volume of Distribution During the Terminal Phase (Vd/F) of Selpercatinib
PK: Vd/F was calculated as CL/F/λZ.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
PK: Mean Residence Time (MRT) of Selpercatinib
PK: MRT represents the average time the drug (selpercatinib) stays in the body.
Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.
Time frame: Baseline up to Week 7
| Milestone | 160 Milligram (mg) Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| Started | 12 | 8 | 8 | 8 |
| Received at least one dose of study drug | 12 | 8 | 8 | 8 |
| Completed | 12 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
PK: Cmax of selpercatinib was reported.
| nanogram per milliliter (ng/mL) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib | 898 ± 129.8 | 1170 ± 78.0 | 732 ± 185.6 | 952 ± 72.3 |
PK: Tmax of Selpercatinib was reported.
| hour | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: Time to Reach Cmax (Tmax) of Selpercatinib | 2.00 (1.00 to 24.00) | 1.53 (1.00 to 2.03) | 2.00 (1.00 to 24.42) | 1.50 (1.00 to 3.00) |
PK: AUC0-t was calculated using the linear trapezoidal rule for increasing and decreasing concentrations.
| hour*nanogram per milliliter (h*ng/ mL) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: Area Under the Concentration-time Curve (AUC), From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib | 17700 ± 65.0 | 20200 ± 43.1 | 14600 ± 74.0 | 27100 ± 33.7 |
PK: Area under the plasma concentration time curve extrapolated to infinity, calculated as AUC(0-t) + Ct/λZ, where Ct is the last measurable concentration and λZ is the apparent terminal elimination rate constant.
| hour*nanogram per milliliter (h*ng/ mL) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | Participants With Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: AUC Extrapolated to Infinity (AUC0-∞) of Selpercatinib | 17700 ± 64.9 | 20200 ± 43.0 | 14700 ± 73.6 | 27300 ± 33.5 |
PK: %AUCextrap of Selpercatinib was reported.
| percentage of (%) of AUCextrap | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: Percentage Extrapolation for AUC (%AUCextrap) of Selpercatinib | 0.422 ± 0.190 | 0.310 ± 0.197 | 0.373 ± 0.328 | 0.685 ± 0.379 |
PK: Apparent terminal elimination rate constant, where λZ is the magnitude of the slope of the linear regression of the log concentration versus-time profile during the terminal phase.
| 1/hour (1/h) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: Apparent Terminal Elimination Rate Constant (λz) of Selpercatinib | 0.0220 ± 61.4 | 0.0266 ± 39.8 | 0.0320 ± 29.0 | 0.0175 ± 28.8 |
PK: Apparent terminal elimination half-life (whenever possible), where t1/2 = natural log (ln)(2)/λZ.
| hour | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: Apparent Terminal Elimination Half-life (t1/2) of Selpercatinib | 36.4 ± 19.9 | 27.9 ± 12.2 | 22.4 ± 6.30 | 41.3 ± 13.5 |
CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC (0-inf), expressed in liter/hour (L/hr).
| Liters per Hour (L/h) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Selpercatinib | 9.03 ± 64.9 | 7.90 ± 43.0 | 10.9 ± 73.6 | 5.87 ± 33.5 |
PK: Vd/F was calculated as CL/F/λZ.
| Liter (L) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: Apparent Volume of Distribution During the Terminal Phase (Vd/F) of Selpercatinib | 411 ± 51.5 | 297 ± 58.0 | 340 ± 68.6 | 336 ± 51.8 |
PK: MRT represents the average time the drug (selpercatinib) stays in the body.
| hour | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| PK: Mean Residence Time (MRT) of Selpercatinib | 25.5 ± 21.9 | 23.3 ± 28.9 | 24.2 ± 39.2 | 34.3 ± 20.2 |
Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.
| participants | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 0 | 0 | 0 | 0 |
Collected over Baseline up to Week 7. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 160 mg Selpercatinib: Normal Hepatic Function | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| 160 mg Selpercatinib: Mild Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| 160 mg Selpercatinib: Moderate Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| 160 mg Selpercatinib: Severe Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/12 | 1/8 | 0/8 | 0/8 |
| Dry mouthGastrointestinal disorders | 0/12 | 1/8 | 0/8 | 0/8 |
| Gastroenteritis viralInfections and infestations | 1/12 | 1/8 | 0/8 | 0/8 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/12 | 1/8 | 0/8 | 0/8 |
| DizzinessNervous system disorders | 0/12 | 1/8 | 0/8 | 0/8 |
| HeadacheNervous system disorders | 1/12 | 1/8 | 0/8 | 0/8 |
| SomnolenceNervous system disorders | 0/12 | 1/8 | 0/8 | 0/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/12 | 0/8 | 0/8 | 0/8 |
All randomized participants.
| Age, Continuous(years) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Mean | 54 ± 5.6 | 59 ± 4.5 | 57 ± 9.0 | 53 ± 4.7 | 56 ± 6.3 |
| Sex: Female, Male(Participants) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Female | 6 | 4 | 6 | 6 | 22 |
| Male | 6 | 4 | 2 | 2 | 14 |
| Ethnicity (NIH/OMB)(Participants) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 1 | 3 | 6 | 19 |
| Not Hispanic or Latino | 3 | 7 | 5 | 2 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 0 | 1 | 4 |
| White | 11 | 6 | 8 | 7 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 160 mg Selpercatinib: Normal Hepatic Function | 160 mg Selpercatinib: Mild Hepatic Impairment | 160 mg Selpercatinib: Moderate Hepatic Impairment | 160 mg Selpercatinib: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| United States | 12 | 8 | 8 | 8 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Oct 2019, 9 months.
Results were first posted in Apr 2025, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib